Eikon Therapeutics updates Q3 2026 corporate presentation; details not disclosed in filing

Eikon Therapeutics, Inc.

Eikon Therapeutics (EIKN) furnished an updated Q3 2026 corporate presentation on August 13, 2026.
Exhibit 99.1 content is truncated in the filing; no financial, pipeline, or operational specifics are available.
CFO Alfred Bowie, Ph.D. signed the current report; no other material events are disclosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.